These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 19524120)
41. Prolactin as a chemoattractant for human breast carcinoma. Maus MV; Reilly SC; Clevenger CV Endocrinology; 1999 Nov; 140(11):5447-50. PubMed ID: 10537179 [TBL] [Abstract][Full Text] [Related]
42. Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo. Bernard V; Lamothe S; Beau I; Guillou A; Martin A; Le Tissier P; Grattan D; Young J; Binart N FASEB J; 2018 Sep; 32(9):4791-4797. PubMed ID: 29596024 [TBL] [Abstract][Full Text] [Related]
43. Prolactin and its receptor as therapeutic targets in glioblastoma multiforme. Asad AS; Nicola Candia AJ; Gonzalez N; Zuccato CF; Abt A; Orrillo SJ; Lastra Y; De Simone E; Boutillon F; Goffin V; Seilicovich A; Pisera DA; Ferraris MJ; Candolfi M Sci Rep; 2019 Dec; 9(1):19578. PubMed ID: 31862900 [TBL] [Abstract][Full Text] [Related]
44. Distribution of prolactin receptors suggests an intraductal role for prolactin in the mouse and human mammary gland, a finding supported by analysis of signaling in polarized monolayer cultures. Ueda EK; Huang K; Nguyen V; Ferreira M; Andre S; Walker AM Cell Tissue Res; 2011 Nov; 346(2):175-89. PubMed ID: 22081226 [TBL] [Abstract][Full Text] [Related]
45. PRL modulates cell cycle regulators in mammary tumor epithelial cells. Schroeder MD; Symowicz J; Schuler LA Mol Endocrinol; 2002 Jan; 16(1):45-57. PubMed ID: 11773438 [TBL] [Abstract][Full Text] [Related]
46. Prolactin Signaling Stimulates Invasion via Na(+)/H(+) Exchanger NHE1 in T47D Human Breast Cancer Cells. Pedraz-Cuesta E; Fredsted J; Jensen HH; Bornebusch A; Nejsum LN; Kragelund BB; Pedersen SF Mol Endocrinol; 2016 Jul; 30(7):693-708. PubMed ID: 27176613 [TBL] [Abstract][Full Text] [Related]
47. Prolactin as an autocrine/paracrine factor in breast tissue. Clevenger CV; Plank TL J Mammary Gland Biol Neoplasia; 1997 Jan; 2(1):59-68. PubMed ID: 10887520 [TBL] [Abstract][Full Text] [Related]
48. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Bogorad RL; Courtillot C; Mestayer C; Bernichtein S; Harutyunyan L; Jomain JB; Bachelot A; Kuttenn F; Kelly PA; Goffin V; Touraine P; Proc Natl Acad Sci U S A; 2008 Sep; 105(38):14533-8. PubMed ID: 18779591 [TBL] [Abstract][Full Text] [Related]
49. Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter. Fang F; Antico G; Zheng J; Clevenger CV BMC Biotechnol; 2008 Feb; 8():11. PubMed ID: 18254957 [TBL] [Abstract][Full Text] [Related]
50. SRC family kinases accelerate prolactin receptor internalization, modulating trafficking and signaling in breast cancer cells. Piazza TM; Lu JC; Carver KC; Schuler LA Mol Endocrinol; 2009 Feb; 23(2):202-12. PubMed ID: 19056863 [TBL] [Abstract][Full Text] [Related]
51. Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro. Langan EA; Ramot Y; Hanning A; Poeggeler B; Bíró T; Gaspar E; Funk W; Griffiths CE; Paus R Br J Dermatol; 2010 May; 162(5):1127-31. PubMed ID: 20302576 [TBL] [Abstract][Full Text] [Related]
52. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Jacobson EM; Hugo ER; Tuttle TR; Papoian R; Ben-Jonathan N Trends Endocrinol Metab; 2010 Nov; 21(11):691-8. PubMed ID: 20846877 [TBL] [Abstract][Full Text] [Related]
53. Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation. Haines E; Minoo P; Feng Z; Resalatpanah N; Nie XM; Campiglio M; Alvarez L; Cocolakis E; Ridha M; Di Fulvio M; Gomez-Cambronero J; Lebrun JJ; Ali S Mol Cell Biol; 2009 May; 29(10):2505-20. PubMed ID: 19273609 [TBL] [Abstract][Full Text] [Related]
55. Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro. Thomas LN; Chedrawe ER; Barnes PJ; Too CKL Breast Cancer Res Treat; 2017 Jul; 164(1):27-40. PubMed ID: 28364216 [TBL] [Abstract][Full Text] [Related]
56. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362 [TBL] [Abstract][Full Text] [Related]
57. Effect of hyperthyroidism on circulating prolactin and hypothalamic expression of tyrosine hydroxylase, prolactin signaling cascade members and estrogen and progesterone receptors during late pregnancy and lactation in the rat. Pennacchio GE; Neira FJ; Soaje M; Jahn GA; Valdez SR Mol Cell Endocrinol; 2017 Feb; 442():40-50. PubMed ID: 27919641 [TBL] [Abstract][Full Text] [Related]
58. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells. Schaber JD; Fang H; Xu J; Grimley PM; Rui H Cancer Res; 1998 May; 58(9):1914-9. PubMed ID: 9581833 [TBL] [Abstract][Full Text] [Related]
59. Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males. Arendt LM; Schuler LA Am J Pathol; 2008 Jan; 172(1):194-202. PubMed ID: 18156207 [TBL] [Abstract][Full Text] [Related]